The diagnostic efficacy of CYFRA21-1 on intrahepatic cholangiocarcinoma: A meta-analysis
- 28 November 2018
- journal article
- research article
- Published by Elsevier BV in Clinics and Research in Hepatology and Gastroenterology
- Vol. 43 (3), 266-272
- https://doi.org/10.1016/j.clinre.2018.10.010
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Prognostic value of serum CYFRA21‐1 and CEA for non‐small‐cell lung cancerCancer Medicine, 2015
- The elevated preoperative neutrophil-to-lymphocyte ratio predicts poor prognosis in intrahepatic cholangiocarcinoma patients undergoing hepatectomyTumor Biology, 2015
- Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic CholangiocarcinomaDigestive Diseases and Sciences, 2014
- The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: A meta-analysisJournal of Cancer Research and Therapeutics, 2014
- QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy StudiesAnnals of Internal Medicine, 2011
- CYFRA21-1 can predict the sensitivity to chemoradiotherapy of non-small-cell lung carcinomaBiomarkers, 2010
- Clinicopathological and prognostic analysis of 429 patientswith intrahepatic cholangiocarcinomaWorld Journal of Gastroenterology, 2009
- Serum Cytokeratin 19 Fragment (CYFRA21-1) as a Prognostic Factor in Intrahepatic CholangiocarcinomaAnnals of Surgical Oncology, 2007
- Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?Journal of Hepatology, 2004
- Towards Complete and Accurate Reporting of Studies of Diagnostic Accuracy: The STARD InitiativeAnnals of Internal Medicine, 2003